Roseleen Charania, MD
Associate Chief Medical Officer for Oncology Programs
Dr. Roseleen Charania is board certified in Internal Medicine, Hematology and Medical Oncology and serves as the Associate Chief Medical Officer for Oncology Programs since April 2024. She is responsible for the overall clinical performance, growth, and development of the company’s Oncology solutions, including medical oncology, radiation oncology, and oncologic imaging. Dr. Charania participates in the strategy, growth and development of the Comprehensive Oncology solution, Precision Medicine, Oncology Benefit Management solution and the Oncology Consult service. She contributes as a program lead for the enterprise-wide oncology strategy and serves as a clinical liaison to Evicore by Evernorth's health-plan clients and the broader physician community. Dr. Charania collaborates with the Enterprise Government affairs team and supports discussions on legislative matters pertaining to oncology regulations. She also collaborates with the Evernorth Research Institute to identify trends in oncology data and develop actionable insights for development of oncology programs and reporting positive clinical impact.
Dr. Charania completed fellowship training at the University of Oklahoma Health Sciences Center and has clinical experience in multi-disciplinary oncology practice, caring for patients with breast, GI and lung cancer and hematological malignancies. She served as an investigator on clinical trials and participated in residency and fellowship training. She is an active member of the American Society of Clinical Oncology and the American Society of Hematology.
Dr. Charania completed fellowship training at the University of Oklahoma Health Sciences Center and has clinical experience in multi-disciplinary oncology practice, caring for patients with breast, GI and lung cancer and hematological malignancies. She served as an investigator on clinical trials and participated in residency and fellowship training. She is an active member of the American Society of Clinical Oncology and the American Society of Hematology.
